- Todos Medical ( OTCQB:TOMDF ) said its majority-owned joint venture 3CL Pharma reported results from the first 100-participant study from an Institutional Review Board-waived market research study of Tollovid in long COVID patients.
- The company said participants in the study were primarily patients with Post-Acute Sequelae of COVID (PASC, or “Long COVID”) as well as participants with acute COVID infection.
- The results to date indicate the participants appear to experience benefit after supplementation with 3CL protease inhibitor immune support supplement Tollovid, the company said.
For further details see:
Todos Medical announces data from 100 participants with Tollovid in long COVID